Year-End Check-In — Let’s Scroll Through CMS’s 2025 Moments Together!

Dermavon Selected for the List of “Deloitte China LSHC Rising Star”

Recently, the 2025 Deloitte China Technology Fast Program Award Ceremony was successfully held in Wuxi, China. After a three-month selection process, Dermavon, the skin health business company of CMS, was included in the list of “Deloitte China LSHC Rising Star” by virtue of its leading innovative product layout in the skin health field, as well as its promising growth and development potential. The theme of this year’s “Technology Fast Program” selection is “Boundless Innovation, Resilient Growth”. Through the review by the Professional Committee, enterprise presentation and scoring, and other processes, the selection comprehensively evaluates enterprise valuation, technological innovation, market prospects, industry ranking, etc., and selects excellent enterprises with both innovation capabilities and growth potential, so as to encourage enterprises to break through technological boundaries and promote the continuous construction of the innovation ecosystem. Being selected into this list is a full recognition of Dermavon’s leading industry position, comprehensive and differentiated innovative product portfolio, […]

CMS: Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China

Povorcitinib is a selective oral small molecule JAK1 inhibitor undergoing clinical development in China. It has been included in the list of Breakthrough Therapeutic Drugsby CDE of China’s NMPA with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.   China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National […]

CMS Included in the Constituent Stocks of the “HKEX Tech 100” Index

Recently, CMS has been successfully selected as a constituent stock of the Hong Kong Exchanges and Clearing Tech 100 Index (“HKEX Tech 100”). As the first Hong Kong stock index launched by HKEX, it aims to track the performance of the 100 largest-cap Hong Kong-listed companies that are highly relevant to the technology theme and eligible for the Southbound Stock Connect, covering six cutting-edge sectors including artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and intelligent driving. Its launch responds to the diversified investment demands of the capital market for the technology sector, providing investors with an efficient tool to allocate assets in leading Hong Kong-listed technology companies. This inclusion fully reflects the capital market’s recognition of CMS’s innovative development strength and investment prospects. CMS is firmly advancing its three core strategies of product innovation, commercial model reform and international expansion, and is gradually achieving the strategic transition to a “specialty-focused, innovation-excellent international […]

CMS: NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China

As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection is able to exert multiple therapeutic effects through explicitly intervening in multiple targets in the ischemic cascade with highly selective synergy. It has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms. The Phase III clinical study in China met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile; the key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals. If approved for marketing, Y-3 for Injection will synergize with other CNS products in expert networks and market resources, including the innovative drug VALTOCO (cluster epilepsy), Deanxit (anxiety, depression), and the improved new drug under NDA review, ZUNVEYL […]

China Medical System: NDA for Atopic Dermatitis Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China

MG-K10 is expected to become the world’s first long-acting anti-IL-4Rαmonoclonal antibody with a four-week dosing frequency to be launched on the market, and has the potential to become the Best-in-Class   Its Phase III clinical study in adults with moderate-to-severe AD in China has achieved positive results, meeting the primary endpoint, and at 52 weeks of treatment with MG-K10, 76.6% of patients achieved an IGA score of 0/1, with an improvement of ≥2 points from baseline; 94.3% and 79.1% of patients achieved EASI 75 and EASI 90, respectively. The overall safety profile was favorable. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10.   The Product will further enrich Dermavon’s portfolio in the AD field. It will generate synergy with ruxolitinib cream(for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and the […]

Awarded for Five Consecutive Years! CMS’s Subsidiary Shenzhen Kangzhe Once Again Listed in “Shenzhen Top 500 Enterprises”

On October 28, the “2025 Shenzhen Top 500 Enterprises” list, released by the Shenzhen Enterprise Confederation and Shenzhen Entrepreneur Association, was officially announced. Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or “the Group”), was once again made the list with honor, ranking at 166th, by virtue of its steady operational performance, outstanding innovation capabilities, and sustained social contributions. Additionally, Shenzhen Kangzhe was also included in the “2025 Top 100 Most Efficient Enterprises of the Shenzhen Top 500” and the “2025 Top 100 Enterprises with the Highest Social Contributions of the Shenzhen Top 500”.     The five consecutive listings of Shenzhen Kangzhe not only reflect the high recognition of its remarkable operational resilience and vibrant innovation vitality in the complex market environment, but also demonstrate the Group’s continuous improvement in scale efficiency and the accelerated release of its quality growth […]

CMS Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®

Ranibizumab Injection (“Lucentis®”) is the first anti-VEGF drug approved for ophthalmic use in China. It is also currently the anti-VEGF drug in China that covers the widest age range and has the most indications[1], with its efficacy and safety verified by more than 200 clinical studies Brolucizumab Injection (“Beovu®”) is the current anti-VEGF drug with the smallest molecular weight (only 26 kDa). The producthas been approved for DME and recommended as a first-line therapy by the authoritative guideline[2]. In the global Phase 3 KESTREL and KITE Studies, Beovu® met all primary efficacy endpoints and the visual benefit persisted until Week 100, while showing superiority in fluid resolution. The median number of injections of Beovu® in the first year (7 times) was lower than that of aflibercept (9 times), while its overall safety profile was comparable to the latter Both collaborative products have been approved for marketing in China, and they will generate strong synergies with CMS Vision’s […]

China Medical System Honored with 2025 Listed Company “Shareholder Return Crystal Ball Award” and “ESG Crystal Ball Award” by Weekly on Stocks

The list of winners for the 2025 Crystal Ball Awards for Listed Companies organized by Weekly on Stocks was recently unveiled. China Medical System Holdings Limited (the “Group” or “CMS”) has been honored with two prestigious awards — the 2025 “Shareholder Return Crystal Ball Award“ and the “ESG Crystal Ball Award“ for Listed Companies — in recognition of its outstanding capital market performance and leading ESG practices. Launched in 2007 by Weekly on Stocks, the “Crystal Ball Awards” have become one of the three most influential annual award programs in China’s capital market, renowned for its professionalism, authority, and impartiality. The awards enjoy broad recognition among regulators, listed companies, and institutional investors. CMS has entered a new stage as “an innovation-driven, multinational pharmaceutical company with a fully integrated R&D, manufacturing, and commercialization value chain“. Currently, the Group’s innovation pipeline has expanded to approximately 40 products, among which 5 innovative drugs have been approved for marketing, and another 5 products are under review for marketing […]

China Medical System: Approval of Drug Clinical Trials for Additional Chronic Obstructive Pulmonary Disease Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection

China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”), for which the Group holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights, has obtained the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 29 September 2025. The NMPA has agreed to conduct the clinical trial of MG-K10 for the treatment of Chronic Obstructive Pulmonary Disease (COPD).   About MG-K10 MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13, for the treatment of type 2 inflammatory diseases. Currently marketed anti-IL-4Rα drugs require biweekly dosing, while MG-K10 has a longer half-life, enabling a four-week dosing frequency. It is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be […]

China Medical System: Approval of Phase III Drug Clinical Trials for Additional Chronic Spontaneous Urticaria Indication of Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection

China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Group on 22 April 2025 for details) together with its subsidiaries holding the co-development rights (except for atopic dermatitis (AD)) and the exclusive commercialization rights of Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”) received the drug clinical trial approval notice issued by National Medical Products Administration (“NMPA”) on 28 September 2025. The NMPA has agreed to conduct a Phase III clinical trial of MG-K10 for chronic spontaneous urticaria (CSU).   About MG-K10 MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13, for the treatment of type 2 inflammatory […]

15 Years of Dedication, Pioneering the Future with Innovation丨China Medical System’s 15th Anniversary of Listing on the Hong Kong Stock Exchange